CTE Blood Test: Two JAMA Studies Point to Detecting the Brain Disease in Living People

CTE Blood Test: Two JAMA Studies Point to Detecting the Brain Disease in Living People
Brain HealthSports MedicineNew Research 2026

CTE Blood Test: Two JAMA Studies Point to Detecting the Brain Disease in Living People

Researchers found that a tau protein fragment in blood tracked advanced chronic traumatic encephalopathy confirmed at autopsy. The test is not FDA-approved or available, and early-stage disease remains out of reach.

DeskHealth and Science DeskChecked againstJAMA study releases from BU, Banner Health and WashU MedicineUpdatedNovember 21, 2026ScopeCTE research, United States

For two decades, chronic traumatic encephalopathy has carried a cruel rule: you can only know for certain after death. Families of former football players, boxers and combat veterans have watched mood swings, memory loss and personality changes unfold without a diagnosis, waiting for a brain autopsy to answer a question the living person never could. This month, two research teams published results in the Journal of the American Medical Association suggesting that a blood draw might one day tell doctors what only a pathologist can confirm today. One researcher called it “a game changer.” The same researchers also said, repeatedly, that it is not ready yet.

The big shift researchers are chasing
From autopsy-only diagnosis to a blood test in life
Two JAMA studies, November 13 and 19, 2026

Why a Blood Test Would Change the Game for CTE

CTE is a degenerative brain disease linked to repeated head impacts, the kind delivered over years of tackling, boxing or exposure to blasts. Its hallmark is an abnormal buildup of tau protein in a pattern that differs from aging or Alzheimer’s disease. Symptoms can include changes in behavior and mood, problems with thinking and memory, and, over time, a gradual loss of movement control. Because the defining tau pattern is only visible under a microscope, doctors currently cannot confirm CTE in a living person.

That gap has practical consequences. Without a way to identify people with the disease while they are alive, researchers cannot easily enroll them in drug trials, track how the disease progresses, or test whether any treatment works. “If this study holds up with future research, if we validate it,” said Michael Alosco, co-director of clinical research at the Boston University CTE Center and co-senior author of one of the studies, the implications would be large. “This is a game changer,” he said.

0FDA-approved tests that diagnose CTE in living people today
4Pathology stages of CTE, from 1 (mild) to 4 (severe)
2Independent JAMA studies published in one week
91.7%CTE rate in 376 ex-NFL brains studied by BU, a biased sample

Inside the Boston University and Banner Health Study

The study published on November 19, 2026, followed 21 former American football players who played at the professional, college and high school levels. All gave blood samples while alive and later donated their brains to the BU CTE Center’s brain bank. Banner Health’s Fluid Biomarker Program at the Banner Sun Health Research Institute in Sun City, Arizona, processed and analyzed the plasma.

When pathologists examined the brains, 18 of the 21 men had CTE. Sixteen had advanced disease, McKee stage 3 or 4, and two had low-stage disease, stage 1 or 2. Three had no CTE. Levels of the blood marker, endogenously cleaved microtubule-binding region tau, or eMTBR-tau, were significantly higher in players with high-stage CTE than in those with low-stage or no CTE. The protein was not elevated in either of those smaller groups.

What autopsies found in the 21 blood donors

Number of former football players by CTE status at autopsy. Source: Boston University and Banner Health, JAMA, November 19, 2026.

All donors studied21
Advanced CTE (stage 3 or 4)16
Low-stage CTE (stage 1 or 2)2
No CTE3

The marker was elevated only in the advanced-stage group, highlighted in magenta.

Nicholas Ashton, co-senior author and senior director of Banner’s Fluid Biomarker Program, compared the work to Alzheimer’s research, where blood tests now cleared by the FDA have been “revolutionary” for diagnosing patients and designing trials. “We are optimistic that the same will be true for CTE,” he said. The researchers cautioned that the blood test is not FDA-approved, is not publicly available, and should not be used for CTE diagnostic decisions until validation studies are complete.

A Second Team, a Larger Sample, a Similar Signal

A week earlier, on November 13, 2026, a team led by WashU Medicine in St. Louis and UCSF published a separate JAMA study using a closely related marker, eMTBR-tau243. The WashU group had previously shown that blood levels of this tau fragment reflect the buildup of tau tangles in Alzheimer’s disease. The new study asked whether it also rises in other “tauopathies,” the family of brain diseases defined by toxic tau.

The study included 229 participants drawn from several biorepositories, beginning with more than 80 people with autopsy-confirmed brain diseases plus healthy volunteers. The researchers then tested blood from 11 people whose CTE was confirmed at autopsy. Levels of eMTBR-tau243 were higher than in healthy people and rose with disease severity, but were much lower than in Alzheimer’s disease. The test distinguished advanced CTE from healthy people with high accuracy but could not reliably identify early-stage CTE.

How many CTE cases the new evidence rests on

Participants and autopsy-confirmed CTE cases in the two November 2026 JAMA studies. Sources: WashU Medicine and BU/Banner Health releases.

WashU/UCSF, all participants229
WashU/UCSF, autopsy-confirmed diseases80+
BU/Banner, all donors21
BU/Banner, confirmed CTE18
WashU/UCSF, confirmed CTE11

Together, the two studies include 29 autopsy-confirmed CTE cases.

“This is not going to be a standalone biomarker,” said Chihiro Sato, co-senior author of the WashU study. Her co-senior author, Kanta Horie, said, “We are potentially opening a new door for diagnosing and treating CTE in living patients.” WashU has licensed the eMTBR-tau243 blood test technology to C2N Diagnostics; the university and some authors disclosed financial interests in the company.

Comparing the Two Studies Side by Side

FeatureBU and Banner HealthWashU Medicine and UCSFWhat it means
Published in JAMANovember 19, 2026November 13, 2026Two independent groups, one week apart
Marker measuredeMTBR-taueMTBR-tau243Closely related tau fragments
Participants21 former football players229 from several brain banksBoth small for a diagnostic test
Confirmed CTE cases18 (16 advanced, 2 early)11Few early-stage cases in either
Main findingElevated only in high-stage CTERises with severity; advanced CTE separated from healthyDetects late, not early, disease
Key limitationSmall sample, no age-matched controlsMuch lower levels than Alzheimer’sNeeds validation and other markers

Compiled from the Boston University, Banner Health and WashU Medicine study releases, November 2026.

What We Know and What Remains Unproven

What We Know

  • Two JAMA studies linked blood eMTBR-tau to autopsy-confirmed CTE.
  • The signal was strongest in advanced CTE, stages 3 and 4.
  • Neither study reliably detected early-stage CTE.
  • The same marker is far higher in Alzheimer’s disease.
  • No CTE blood test is FDA-approved or commercially available.

What Is Still Unclear

  • Exact accuracy figures in larger, more diverse groups.
  • Whether the test works in women, non-athletes and veterans.
  • How early in the disease a blood marker could turn positive.
  • Whether a five-year timeline to a commercial test is realistic.

The Alzheimer’s Problem: Why One Marker Is Not Enough

The biggest scientific hurdle is overlap. eMTBR-tau reflects tau tangles, and Alzheimer’s disease produces tau tangles too, at much higher levels. A raised result therefore does not neatly label a sample “CTE.” Alosco said the marker is elevated in both diseases, and other markers such as p-tau217, which tracks Alzheimer’s-type changes, would likely be needed to tell them apart.

Sato described how a future test might work in practice: a positive tau result in someone with a history of repeated head injury who tests negative for Alzheimer’s “might be CTE.” In other words, the blood test would be one piece of a diagnostic puzzle that also includes exposure history, symptoms, clinical exams and possibly brain imaging. The researchers proposed this combination; it has not been tested as a clinical pathway.

Hypothetical result patternTau markerAlzheimer’s markerPossible interpretation
Head-impact history, symptomsHighNegativeMay suggest advanced CTE, per researchers
Head-impact history, symptomsHighPositiveAlzheimer’s likely; CTE cannot be separated
Head-impact history, symptomsNormalNegativeDoes not rule out early CTE
No head-impact historyHighPositivePoints toward Alzheimer’s disease
No head-impact historyNormalNegativeNo tau signal detected

Illustrative only, based on how study authors described potential future use. Not a validated diagnostic pathway.

Twenty Years of CTE Research, in Eight Snapshots

  1. 2005First published report of CTE in a former NFL player.
  2. 2017BU reports CTE in 110 of 111 former NFL players’ brains studied.
  3. 2018BU finds CTE in 1 of 164 Framingham community brains.
  4. 2021Consensus criteria define traumatic encephalopathy syndrome in life.
  5. 2023BU brain bank count reaches 345 of 376 former NFL players.
  6. 2025FDA clears the first blood test to aid Alzheimer’s diagnosis.
  7. Nov 13, 2026WashU and UCSF study of 229 people published in JAMA.
  8. Nov 19, 2026BU and Banner study of 21 donors published in JAMA.
CTE rates in brain studies depend heavily on who donates

Percent of brains with CTE. Sources: Boston University CTE Center (2017, 2023, 2018 Framingham comparison) and a Harvard-led study of 338 former NFL players reported in 2026. Brain bank samples are subject to selection bias and do not show true prevalence.

BU, 2017 (110 of 111 NFL)99%
BU, 2023 (345 of 376 NFL)91.7%
Harvard-led, 338 NFL25%+
Framingham community, 1640.6%

The spread in those numbers is itself a lesson. Brain banks such as BU’s receive brains disproportionately from families who saw symptoms, which inflates the rate. The BU CTE Center itself warns that its figures should not be read to mean that 91.7% of all current and former NFL players have CTE. A blood test, if validated, could finally let researchers measure how common the disease really is among living people.

A Worked Example: Why Accuracy Depends on Who Gets Tested

Even an accurate test can mislead when it is used on the wrong population. The numbers below are hypothetical, chosen only to show the arithmetic. Neither study published these accuracy figures.

Same test, two very different groups

General population, 1% with CTE
  • People tested10,000
  • Actually have CTE100
  • True positives at 90% sensitivity90
  • False positives at 90% specificity990
  • Chance a positive is realabout 8%
Symptomatic ex-players, 50% with CTE
  • People tested10,000
  • Actually have CTE5,000
  • True positives at 90% sensitivity4,500
  • False positives at 90% specificity500
  • Chance a positive is real90%

Hypothetical illustration of positive predictive value. Prevalence and accuracy figures are invented for the arithmetic and are not estimates of real CTE rates or test performance.

That is why researchers talk about using the test first in people at high risk who already have symptoms, such as former football players, boxers and combat veterans, rather than as a screening test for the public. It is also why a negative result would not rule out early disease, given that neither study could reliably detect low-stage CTE.

What people get wrong
  • Believing a CTE blood test is available now; it is experimental.
  • Assuming a positive tau result means CTE; Alzheimer’s raises it far more.
  • Reading brain bank rates as true prevalence among all NFL players.
  • Expecting the test to catch early disease; both studies found it did not.
  • Thinking CTE only affects pro players; donors included college and high school players.

What Former Players and Families Can Do Now

For people worried about their own brain health after years of contact sports or military blast exposure, the advice from researchers is to act on what is known today rather than wait for a future test. The Banner Health team recommended that anyone concerned see a clinician who specializes in neurodegenerative conditions and address modifiable risk factors that support brain health.

Step 1

Write down your exposure: years of play or service, positions, and the number of diagnosed concussions.

Step 2

Track symptoms over 3 to 6 months: mood, memory, attention, sleep and movement changes.

Step 3

See a neurologist or memory clinic that evaluates traumatic encephalopathy syndrome.

Urgent

Seek help immediately for thoughts of self-harm; call or text 988 in the U.S.

  1. Treat what can be treated now: depression, sleep apnea, headaches, blood pressure and hearing loss.
  2. Avoid offers of unvalidated “CTE tests”; none is approved.
  3. Ask about research studies that follow living participants with head-impact histories.
  4. Consider brain donation registration, which fuels studies like these two.
Fact box: traumatic encephalopathy syndrome

Because CTE cannot yet be confirmed in life, a 2021 consensus defined traumatic encephalopathy syndrome, or TES, as a clinical diagnosis based on substantial repeated head impacts plus core symptoms such as cognitive impairment or neurobehavioral changes. A future blood test could help link a TES diagnosis to the underlying CTE pathology.

Fact box: why drug trials need this

WashU researchers said a validated blood test could enable trials of drugs that target harmful tau. Without a way to identify people with CTE while alive, no treatment can be properly tested, which is why both teams framed the test as a door to future therapies rather than a diagnosis on its own.

Frequently Asked Questions

Is there a blood test for CTE?

Not yet for clinical use. Two November 2026 JAMA studies found that a tau protein fragment in blood was elevated in people with advanced CTE confirmed at autopsy, but the test is experimental, not FDA-approved and not available to the public.

How is CTE diagnosed now?

CTE can be definitively diagnosed only after death, by examining brain tissue for a specific pattern of abnormal tau protein. In living people, doctors can diagnose traumatic encephalopathy syndrome based on head-impact history and symptoms.

What did the new CTE blood test study find?

In a Boston University and Banner Health study of 21 former football players, 18 had CTE at autopsy. Blood levels of eMTBR-tau were significantly higher in the 16 with advanced CTE than in those with early or no CTE.

When will a CTE blood test be available?

Researchers have said they hope a commercially available test could exist within about five years, but it first needs larger validation studies and regulatory review.

Can the CTE blood test detect early CTE?

Not reliably. Both studies found the marker was elevated mainly in advanced CTE, stages 3 and 4. Early-stage cases were few and were not reliably detected.

Why does Alzheimer’s complicate a CTE blood test?

The tau fragment measured is also elevated in Alzheimer’s disease, at much higher levels. Researchers expect a CTE test would need to be combined with Alzheimer’s markers and clinical history.

What percentage of NFL players have CTE?

No one knows the true rate. Boston University found CTE in 345 of 376 former NFL players’ brains studied, but its brain bank is subject to selection bias. A Harvard-led study of 338 former players found at least 1 in 4 had CTE.

Who is at risk of CTE?

People with repeated head impacts, including football players at all levels, boxers and military veterans exposed to blasts. Researchers say longer exposure is associated with higher risk.

The Two-Minute Drill

Two JAMA studies published in November 2026 found that a tau fragment in blood, eMTBR-tau, tracked advanced CTE confirmed at autopsy. The Boston University and Banner Health study involved 21 former football players; the WashU and UCSF study included 229 people, 11 with CTE. Both detected late-stage disease but not early CTE, and the marker is much higher in Alzheimer’s. Researchers call it a potential game changer for diagnosis and drug trials, hope for a commercial test within about five years, and stress that no CTE blood test is approved today.

Sources

  • Boston University CTE Center and Banner Health, CTE blood biomarker study, JAMA (November 19, 2026), as reported by AZFamily, NBC Sports and Scientific American
  • WashU Medicine, “Progress toward a blood test for CTE,” JAMA study by Horie, Sato and colleagues (November 13, 2026)
  • PhillyVoice, “Biomarkers linked to CTE may be a ‘game changer'” (November 19, 2026)
  • Boston University CTE Center, 345 of 376 former NFL players release (February 2023) and 2018 Framingham comparison
  • 2021 consensus diagnostic criteria for traumatic encephalopathy syndrome

Details current as of November 21, 2026. Research findings are preliminary; check the published studies for full methods and results.

This article is general information and is not medical advice. It is not an official communication from Boston University, Banner Health, WashU Medicine, UCSF or any regulator. The worked example uses hypothetical numbers. If you are concerned about your brain health, talk to a qualified clinician.

21c775d4814f0f0bdd44d583c3f2565d146349c4cd34f66befe6dcb1b39a55eb?s=150&d=mp&r=g
Website | + posts

Omisha is a health writer passionate about turning complex medical research into clear, actionable content readers can trust. She covers everything from nutrition and mental wellness to chronic disease management, always grounding her work in credible science and real-world relevance. When she's not writing, she's usually reading up on the latest health studies or exploring new wellness trends to write about next.

Omisha

Omisha

Omisha is a health writer passionate about turning complex medical research into clear, actionable content readers can trust. She covers everything from nutrition and mental wellness to chronic disease management, always grounding her work in credible science and real-world relevance. When she's not writing, she's usually reading up on the latest health studies or exploring new wellness trends to write about next.

Leave a comment

Your email address will not be published.